WuXi STA and Antengene Sign Development and Manufacturing Agreement

Shanghai, July 24, 2018: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Antengene Corporation, a…

WuXi STA first CDMO to support the approval of an innovative drug in China through the “MAH” pilot

WuXi STA enables Ascletis to receive NDA Approval from China FDA for Ganovo® Shanghai, June 15, 2018: STA Pharmaceutical Co., Ltd. (WuXi…

• Archives

WuXi STA Changzhou Site Passes First U.S. FDA Inspection

The integrated R&D and manufacturing facility is expecting more products to go into commercial production post approval Shanghai, May 11,…

• Archives

WuXi STA to build new R&D center in Shanghai

New Delhi, April 30, 2018: WuXi STA has already established an industry leading process development platform with over 1,000 scientists…

Phoenix Molecular Designs Announces Manufacturing Collaboration with WuXi STA to advance PMD-026 toward IND

MD-026 is the first RSK inhibitor to demonstrate potential disease-modifying properties in triple-negative breast cancer (TNBC)  Vancover, April 19, 2018: Phoenix…

WuXi STA and Regulus Announce microRNA Development and Manufacturing Collaboration

Agreement follows the recent opening of WuXi STA’s oligonucleotide R&D labs in China and the USA. Shanghai, May 03, 2018: STA…